There are currently 169 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
The Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Recruiting
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/20/2023
Locations: Teton Cancer Institute, Idaho Falls, Idaho +1 locations
Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Register for Updates
Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.
NCT00591552
Recruiting
In an effort to elucidate whether the Harmonic Scalpel will improve sealing lymphatics and decrease lymphatic drainage thereby decreasing the length of time that chest tubes are required and minimizing length of stay; the Harmonic Scalpel will be compared to a control group which uses electrocautery. This study will assess these two different methods to determine if there is a notable decrease in the amount of drainage with one versus the other.
Gender:
All
Ages:
Between 20 years and 75 years
Trial Updated:
11/20/2023
Locations: Sentara Norfolk General Hospital/Sentara Heart Hospital, Norfolk, Virginia
Conditions: Lung Cancer
Register for Updates
Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy
NCT05342675
Recruiting
Pneumothorax is the most common complication after CT-guided lung biopsy, and several techniques have been proposed to reduce the risk. Among them, rapid rollover is the maneuver to immediately reposition the patient, with biopsy-side down after removal of biopsy needle. It has been theorized that the technique reduces the size of alveoli surrounding the needle tract, leading to airway closure and reduction in the alveolar-to-pleural pressure gradient, thereby preventing pneumothorax. The aim of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California +1 locations
Conditions: Lung Cancer, Pneumothorax
Register for Updates
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
NCT05452005
Recruiting
This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer
Register for Updates
UNC Pleural Fluid Registry
NCT05620329
Recruiting
Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid regi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: UNC Lingeberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
Register for Updates
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
NCT00900419
Recruiting
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Gender:
All
Ages:
Between 21 years and 90 years
Trial Updated:
11/14/2023
Locations: University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado
Conditions: Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
Register for Updates
Study of Trilaciclib and Lurbinectidin
NCT05578326
Recruiting
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire +1 locations
Conditions: Lung Cancer, Small-cell Lung Cancer
Register for Updates
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
NCT03693014
Recruiting
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy called stereotactic body radiation therapy (SBRT). SBRT is a commonly used type of radiation therapy that gives high dose radiation with high precision to tumors in 1-5 treatments. Radiation therapy, such as SBRT can also treat sites of metastases. The use of checkpoint inh... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Hartford Healthcare, Hartford, Connecticut +9 locations
Conditions: Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
Register for Updates
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764
Recruiting
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Arizona Oncology, Tucson, Arizona +20 locations
Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Register for Updates
Increasing Adherence to Lung Cancer Screening
NCT05832008
Recruiting
Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) & diagnostic follow-up across eligible primary care clinicians & patients. Following the trial, a subsample of patients & clinicians will be invited to one-time semi-structured interview & survey to identify individual & system-level factors that may restrict or enhance the impact of strategies.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
11/10/2023
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Adherence, Patient
Register for Updates
Metabolic Biomarkers in Thoracic Cancers
NCT02095808
Recruiting
The purpose of this research study is to develop a method of using magnetic resonance imaging (MRI) to evaluate lung tumors and other thoracic malignancies. An MRI is a scanning device that uses magnets to make images (pictures) of the body. This study is being done to determine what series of reactions (metabolic pathways) pulmonary nodules use as they burn sugar as fuel for growth. The manner in which the tumor burns (metabolizes) sugar for fuel is being investigated by using a natural, slight... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Lung Cancer
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
10/27/2023
Locations: University of North Carolina-Chapel Hill, Carrboro, North Carolina +2 locations
Conditions: Lung Cancer
Register for Updates